Urological Research

, Volume 14, Issue 4, pp 211–215 | Cite as

Histopathology of BCG and thiotepa treated bladders

  • P. Guinan
  • M. Shaw
  • V. Ray
Bladder Cancer


In an effort to characterize the pathophysiological differences between the modes of action of BCG and thiotepa in the treatment of superficial bladder cancer, normal female rats received weekly intravesical instillations of both agents. The animals were sacrificed and their bladders were examined pathologically to determine if there were histological differences between the cellular infiltrates found in the BCG and thiotepa treated bladders. Monomuclear cells, particularly T-cells, predominated in the BCG treated bladders whereas polymorphonucleated cells predominated in the thiotepa treated bladders suggesting that there may be an immune aspect to the former therapy. The presence of T-cells following BCG therapy suggests a T-cell mediated immune response.

Key words

Intravesical chemotherapy BCG Thiotepa 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Morales A, Eidiner D, Bruce AW (1976) Intracavitary bacillus calmette guerin in the treatment of superficial bladder tumors. J Urol 116:180–183Google Scholar
  2. 2.
    Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128:27–30Google Scholar
  3. 3.
    Lamm DL, Thor DE, Stogdill VD, Radwin HM (1982) Bladder cancer immunotherapy. J Urol 128:931–935Google Scholar
  4. 4.
    Veenema RJ, Dean AL, Uson AC, Roberts M, Longo E (1969) Thio-tepa bladder instillations: Therapy and prophylaxis for superficial bladder tumors. J Urol 101:711Google Scholar
  5. 5.
    Connors TN (1976) Chemotherapy with cytotoxic agents. In: Symington T, Carter R (eds) Scientific foundation of oncology. Year Book Publisher, Chicago, pp 623–632Google Scholar
  6. 6.
    Nieh PT, Daly JJ, Irwin RJ, Prout GR (1979) Intravesical Thiotepa: A study of H-Thymidine uptake in normal urothelium and FANFT-induced tumors in rats. Invest Urol 4:486–488Google Scholar
  7. 7.
    Williams AF, Galtre C, Milstein C (1977) Analysis of cell surfaces by xenogenic myeloma-hybrid antibodies. Differentiation antigens of rat lymphocytes. Cell 12:663–673Google Scholar
  8. 8.
    Brideou RJ, Carter PB, McMaster WR, Masen DW, Williams AF (1980) Two subsets of rat T lymphocytes defined with monocloral antibodies. Eur J Immunol 10:609–615Google Scholar
  9. 9.
    Shapiro A, Kadmon D, Catalona WJ, Ratliff TL (1982) Immunotherapy of superficial bladder cancer. J Urol 128:891–894Google Scholar
  10. 10.
    Netto NR, Lemos GC (1983) A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. J Urol 129:33–34Google Scholar
  11. 11.
    Lajzerowcz M, Thomson DMP, Reid EC (1982) A study of the immune response to the organ specific neoantigen of human bladder cancer. J Urol 128:1122–1129Google Scholar
  12. 12.
    Adolphs HD, Bastian HP (1983) Chemoimmune prophylaxis of superficial bladder cancer. J Urol 129:29–32Google Scholar
  13. 13.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1984) Comparison of the efficacy of intravesical bacillus Calmette-Guerin with thiotepa, mitomycin C, poly I: C/poly L-lysin and cis platinum in murine bladder cancer. J Urol 131:139–143Google Scholar
  14. 14.
    Guerin C (1957) The history of BCG. In: Rosenthal S (ed) BCG vaccination against tuberculosis. Little Brown and Co, Boston, pp 48–53Google Scholar
  15. 15.
    Pearl R (1929) Cancer and tuberculosis. Am J Hyg 9:97–159Google Scholar
  16. 16.
    Davignon LP, Robillard P, Lemande P, Froppier A (1970) BCG vaccination and leukemia mortality. Lancet II:638Google Scholar
  17. 17.
    Stjernsward J (1966) Effect of bacillus Calmette-Guerin and/or methylcholanthrene on the antibody forming cells measured at the cellular level by a hemolytic plaque test. Cancer Res 26:1591–1594Google Scholar
  18. 18.
    Pollack SB (1977) Effector cells for antibody dependent cell mediated cytotoxicity. I. Increased cytotoxicity after priming with BCG-SS. Cell Immunol 29:272–281Google Scholar
  19. 19.
    Baldwin RW, Pimm MV (1937) BCG immunotherapy of pulmonary growths from intravenously transferred rat tumor cells. Br J Cancer 27:48–54Google Scholar
  20. 20.
    Senelar R, Bureau A, Serre D, Theumynck D, Serrow B (1977) Thymic and splenic changes following injection of living bruella and BCG in the guinea pig: Ca. Immunol Immunother 3:15–22Google Scholar
  21. 21.
    Mackaness GB, Lagrange PH, Ishibash T (1947) The modifying effect of BCG on the immunological induction of T cells. J Exp Med 139:1540–1552Google Scholar
  22. 22.
    Fisher B, Taylor S, Levin M, Saffer E, Fisher ER (1974) Effect of Mycobacterium bovis (strain of bacillus Calmette-Guerin) on macrophage production by the bone marrow of tumor-bearing mice. Cancer Res 34:1668–1670Google Scholar
  23. 23.
    Wolf SA, Tracey DE, Henny CS (1976) Induction of “natural killer” cells by BCG. Nature 262:584–596Google Scholar
  24. 24.
    Niitsuma M, Golub H, Sidney ER, Holmes EC (1981) Lymphoid cells infiltrating human pulmonary tumors: Effect of intralesional BCG injection. J NCI 67:997–1003Google Scholar
  25. 25.
    Pouillart P, Palangie T, Schwarzenberg L, Brugerie H, Lheritier J, Mathe G (1975) Effect of BCG on haemopoietic stem cells. Biomedicine 23:469–471Google Scholar
  26. 26.
    Bast RC, Bast BS (1976) Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann NY Acad Sci 277:60Google Scholar
  27. 27.
    Bast RC Jr, Zaar B, Borsos T, Rapp HJ (1974) BCG and cancer. N Engl J Med 290:1413–1420Google Scholar
  28. 28.
    Baldwin RW, Pimm MV (1973) BCG immunotherapy of pulmonary growths from intravenously transferred rat tumor cells. Br J Cancer 27:48–54Google Scholar
  29. 29.
    Pimm MV, Hopper DG, Baldwin RW (1976) BCG treatment of malignant plueral effusions in the rat. Br J Cancer 34:368–373Google Scholar
  30. 30.
    Albert NE, Sparks FC, Lytton B (1978) The effect of intramural injection of immunotherapeutic agents on bladder histology and systemic humoral response. Invest Urol 2:134–139Google Scholar
  31. 31.
    Lamm D, Thor D, Harris I, Stogdill V, Radwin H (1982) Intravesical and percutaneous BCG immunotherapy of recurrent superficial bladder cancer. In: Terry W, Rosenberg S (eds) Immunotherapy of human cancer. Excerpta Medica, New York, pp 315–327Google Scholar
  32. 32.
    Willie AG, Sparks FC, Morton DL (1977) Monitoring immunotherapy with bacillus Calmette-Guerin by antibody titer. Cancer Res 37:2251–2256Google Scholar
  33. 33.
    Winters WD, Lamm DL (1981) Antibody responses to bacillus Calmette-Guerin during immunotherapy in bladder cancer patients. Cancer Res 41:2671–2676Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • P. Guinan
    • 1
    • 2
  • M. Shaw
    • 1
    • 2
  • V. Ray
    • 1
    • 2
  1. 1.Division of UrologyCook CountyChicagoUSA
  2. 2.Division of UrologyThe University of Illinois HospitalsChicagoUSA

Personalised recommendations